Skip to main content
European Commission logo print header

Multidisciplinary approach to understanding the pathophysiology of the wiskott-aldrich syndrome towards improved healthcare.

Article Category

Article available in the following languages:

Shedding light on Wiskott-Aldrich syndrome

For many years little was known about the mechanisms involved in the pathological state induced by the Wiskott-Aldrich syndrome (WAS). WAS is a rare genetic condition of the blood, which if untreated leads to death. Increasing the available knowledge on WAS is a crucial step towards developing novel treatments for the condition.

Health icon Health

The WASPNEST project concentrated on the genetic and molecular aspects of the disease and resulted in a number of new findings. Research revealed that alterations in the WAS gene can lead to increased levels of apoptotic cell death. Furthermore, it was shown that increased and unregulated expression of the WAS gene leads to premature cell death. This implies that the WAS protein (WASp) is toxic over a certain threshold and could in fact be involved in a number of other conditions. WAS is characterized by a marked drop in levels of particular cell types in the blood (thrombocytopenia and neutropenia), affecting the immune system and the blood cells' abilities to regenerate. WAS patients demonstrate an increased susceptibility to viral infections and it is likely that the reason behind that phenomenon is WASp's direct involvement in the activation of the immune system's defensive pathways in healthy individuals. Regulating the expression of the WAS gene could present a novel method of therapeutic intervention. Current treatment involves haematopoietic stem cell transplantation. Gene therapy presents a viable option for treatment, and it is likely that the conclusions of WASPNEST project could aid towards the development of novel therapies.

Discover other articles in the same domain of application